Physician profile
Mark Hampton Blocker
NPI 1104321397
$8,401.37
in general payments reported to CMS, 2019-2025
25 companies · $1,821 in 2025
The $1,821 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $943 · 2022: $1,373 · 2023: $2,024 · 2024: $2,241 · 2025: $1,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,085.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,578.66 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $930.24 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $801.49 | 2021-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $673.50 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $542.65 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $445.16 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $395.70 | 2021-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $389.59 | 2021-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $346.81 | 2023-2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $301.81 | 2024-2025 | Ingrezza |
| Corium, LLC | $299.66 | 2021-2025 | Azstarys |
| Alkermes, INC. | $264.29 | 2021-2024 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $239.88 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $236.32 | 2021-2025 | Fanapt |
| Lundbeck LLC | $219.64 | 2021-2025 | Rexulti, Abilify Maintena |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $181.86 | 2023-2024 | Auvelity |
| Neos Therapeutics, LP | $162.58 | 2022-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sunovion Pharmaceuticals INC. | $88.93 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $80.36 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Bausch Health US, LLC | $73.65 | 2024-2025 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $67.77 | 2025 | Cobenfy |
| Aytu Biopharma, INC. | $35.37 | 2022 | |
| Eisai INC. | $15.73 | 2021 | |
| Vertical Pharmaceuticals, LLC | $15.44 | 2024 | Relexxii |
| Idorsia Pharmaceuticals US INC | $14.28 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Blocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.